GENETRON HOLDINGS LIMITED Inactive Instrument
Genetron Holdings Limited Stock
Equities
GTH
US37186H2094
Biotechnology & Medical Research
|
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4.025 USD | +0.12% |
|
+0.12% | +9.38% |
| Mar. 29 | Genetron Holdings Limited(NasdaqGM:GTH) dropped from NASDAQ Composite Index | CI |
| Mar. 28 | New Genetron Holding Limited completed the acquisition of Genetron Holdings Limited | CI |
More news
More press releases
| Managers | Title | Age | Since |
|---|---|---|---|
Si Zhen Wang
CEO | Chief Executive Officer | 48 | 14-12-31 |
Hai Yan
FOU | Founder | 57 | 14-12-31 |
Ce Xu
DFI | Director of Finance/CFO | 43 | 18-02-28 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Dian Kang
BRD | Director/Board Member | 76 | 20-05-31 |
Wing Kee Lau
BRD | Director/Board Member | 60 | 20-05-31 |
Shan Fu
BRD | Director/Board Member | 56 | 21-05-31 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.01% | 0 M€ | 0.00% | - | |
| 0.00% | 2 M€ | -.--% | ||
| 0.00% | 117 M€ | +0.83% | - |
Genetron Holdings Limited is a precision oncology company that specializes in cancer molecular profiling and harnesses technologies in molecular biology and data science to transform cancer treatment. The Company has developed a comprehensive product and service portfolio that cover the full-cycle of cancer care from early screening, to diagnosis and treatment recommendations, to continuous monitoring and continuous care. The Company operates its businesses primarily within the China market.
Calendar
2024-05-19
- Q1 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| +3.13% | 42.11B | |
| +48.83% | 40.08B | |
| +8.49% | 40B | |
| -10.82% | 26.87B | |
| +8.26% | 24.58B | |
| -23.69% | 18.44B | |
| +1.58% | 11.94B | |
| +32.83% | 11.66B | |
| +6.63% | 11.01B |
- Stock Market
- Equities
- GTH Stock
